kabutan

Linical Co., Ltd.(2183) Summary

2183
TSE Standard
Linical Co., Ltd.
294
JPY
-1
(-0.34%)
Dec 12, 3:30 pm JST
1.88
USD
Dec 12, 1:30 am EST
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
PBR
1.10
Yield
5.44%
Margin Trading Ratio
Stock Price
Dec 12, 2025
Opening Dec 12, 9:00 am
296 JPY 1.90 USD
Previous Close Dec 11
295 JPY 1.88 USD
High Dec 12, 9:42 am
297 JPY 1.90 USD
Low Dec 12, 9:29 am
293 JPY 1.88 USD
Volume
70,600
Trading Value
0.02B JPY 0.13M USD
VWAP
294.63 JPY 1.89 USD
Minimum Trading Value
29,400 JPY 188 USD
Market Cap
7.27B JPY 0.05B USD
Number of Trades
79
Liquidity & Number of Trades
As of Dec 12, 2025
Liquidity
Mid
1-Year Average
55
1-Year High Jan 30, 2025
296
Margin Trading
Date Short Interest Long Margin Positions Ratio
Dec 5, 2025 0 115,000
Nov 28, 2025 0 155,400
Nov 21, 2025 0 102,600
Nov 14, 2025 0 150,200
Nov 7, 2025 0 103,600
Company Profile
Linical Co., Ltd. specializes in contract research for pharmaceutical development, focusing on Phase II and III clinical trials. The company also provides support for pharmaceutical sales.
Sector
Services
Linical Co., Ltd. primarily engages in Contract Research Organization (CRO) services for pharmaceutical development, while also offering post-marketing support services for pharmaceuticals. In its CRO business, the company undertakes various tasks including clinical trial monitoring, quality control, data management, statistical analysis, and medical writing for documents such as clinical trial protocols. Additionally, Linical provides drug discovery support services, offering consulting on development strategy planning, regulatory affairs, and approval applications for biotech venture companies. In its post-marketing support business, Linical handles planning, monitoring, and auditing services. Through these operations, Linical offers comprehensive global services spanning from drug discovery support to clinical development, and post-approval lifecycle management, including post-marketing clinical trials and research.